Gabriel Kremmidiotis

2.0k total citations
46 papers, 1.6k citations indexed

About

Gabriel Kremmidiotis is a scholar working on Molecular Biology, Cancer Research and Cell Biology. According to data from OpenAlex, Gabriel Kremmidiotis has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 10 papers in Cancer Research and 8 papers in Cell Biology. Recurrent topics in Gabriel Kremmidiotis's work include Cancer, Hypoxia, and Metabolism (7 papers), Cancer Genomics and Diagnostics (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Gabriel Kremmidiotis is often cited by papers focused on Cancer, Hypoxia, and Metabolism (7 papers), Cancer Genomics and Diagnostics (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Gabriel Kremmidiotis collaborates with scholars based in Australia, United States and Netherlands. Gabriel Kremmidiotis's co-authors include David F. Callen, Peter D’Eustachio, Lisa M. Guay‐Woodford, Bradley K. Yoder, Xiaoying Hou, Michal Mrug, Elliot J. Lefkowitz, David R. Beier, Alison Gardner and Annabell F. Leske and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Gabriel Kremmidiotis

45 papers receiving 1.6k citations

Peers

Countries citing papers authored by Gabriel Kremmidiotis

Since Specialization

Citations

This map shows the geographic impact of Gabriel Kremmidiotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Kremmidiotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Kremmidiotis more than expected).

Fields of papers citing papers by Gabriel Kremmidiotis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Kremmidiotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Kremmidiotis. The network helps show where Gabriel Kremmidiotis may publish in the future.

Co-authorship network of co-authors of Gabriel Kremmidiotis

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Kremmidiotis. A scholar is included among the top collaborators of Gabriel Kremmidiotis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Kremmidiotis. Gabriel Kremmidiotis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103) 2018 ·Cancer Chemotherapy and Pharmacology ·(unknown), Kristina Lindemann, Philip Beale, Emma Rossi, (unknown), Michelle Vaughan, Meaghan Tenney, Julie Martyn, Dirkje W. Sommeijer, J. L. Mesías Iglesias, Gabriel Kremmidiotis, Jeremy A. Simpson, (unknown), Tina C. Lavranos, Annabell F. Leske, (unknown), David Espinoza, Martin R. Stockler, Danny Rischin	3
2	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma 2013 ·Lung Cancer ·Anna K. Nowak, Chris Brown, Michael Millward, Jenette Creaney, Michael Byrne, Brett Hughes, Gabriel Kremmidiotis, David C. Bibby, Annabell F. Leske, Paul Mitchell, Nick Pavlakis, Michael Boyer, Martin R. Stockler	44
3	A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial. 2013 ·Journal of Clinical Oncology ·John Sarantopoulos, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn Bylow, C. Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, (unknown), Tina C. Lavranos, J. L. Mesías Iglesias, Guru Sonpavde, Theodore F. Logan, Noah M. Hahn, Christopher J. Sweeney, Thomas E. Hutson, (unknown)	1
4	Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group). 2012 ·Journal of Clinical Oncology ·Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Theodore F. Logan, Kathryn Bylow, Matt D. Galsky, David C. Bibby, Gabriel Kremmidiotis, (unknown), Tina C. Lavranos, Annabell F. Leske, Noah M. Hahn, Guru Sonpavde, Christopher Sweeney, John Sarantopoulos, (unknown)	2
5	Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation 2011 ·Clinical Cancer Research ·Danny Rischin, David C. Bibby, Geoff Chong, Gabriel Kremmidiotis, Annabell F. Leske, (unknown), Shirley Wong, Mark Rosen, Jayesh Desai	54
6	Abstract 662: Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models 2011 ·Cancer Research ·Tina C. Lavranos, Annabell F. Leske, (unknown), (unknown), Gabriel Kremmidiotis	2
7	Discovery and clinical development of BNC105, a tubulin targeting small molecule that selectively disrupts the vasculature in solid tumours 2011 ·(unknown), (unknown), (unknown), (unknown), (unknown), Danny Rischin, Jayesh Desai, (unknown), (unknown), Bernard L. Flynn, Gabriel Kremmidiotis	1
8	BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy 2010 ·Molecular Cancer Therapeutics ·Gabriel Kremmidiotis, Annabell F. Leske, Tina C. Lavranos, (unknown), (unknown), (unknown), Michael O’Callaghan, (unknown), Bernard L. Flynn	69
9	Abstract #5564: BNC105 is a tubulin targeting agent that is not susceptible to efflux by Pgp transporter expression, and yields additive therapeutic benefit when combined with other anti-cancer agents 2009 ·Cancer Research ·Gabriel Kremmidiotis, (unknown), (unknown), (unknown), (unknown), Reneé Phillips, David C. Bibby, Annabell F. Leske	1
10	ZNF652, A Novel Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription 2006 ·Molecular Cancer Research ·Raman Kumar, Jantina Manning, Hayley E. Spendlove, Gabriel Kremmidiotis, (unknown), Jaclyn Lee, (unknown), Kelly M. Cheney, Martha R. Stampfer, Prem P. Dwivedi, Howard A. Morris, David F. Callen	43
11	Aberrant CBFA2T3B gene promoter methylation in breast tumors. 2004 ·Molecular Cancer ·Anthony J. Bais, Alison Gardner, (unknown), David F. Callen, Grant R. Sutherland, Gabriel Kremmidiotis	12
12	The de novo chromosome 16 translocations of two patients with abnormal phenotypes (mental retardation and epilepsy) disrupt the A2BP1 gene 2004 ·Journal of Human Genetics ·Kavita Bhalla, Hilary A. Phillips, Joanna Crawford, (unknown), John C. Mulley, Helen J. Eyre, Alison Gardner, Gabriel Kremmidiotis, David F. Callen	121
13	Sequencing, Transcript Identification, and Quantitative Gene Expression Profiling in the Breast Cancer Loss of Heterozygosity Region 16q24.3 Reveal Three Potential Tumor-Suppressor Genes 2002 ·Genomics ·Jason A. Powell, Alison Gardner, Anthony J. Bais, (unknown), Elizabeth Baker, S.A. Whitmore, Joanna Crawford, Marina Kochetkova, Hayley E. Spendlove, Norman A. Doggett, Grant R. Sutherland, David F. Callen, Gabriel Kremmidiotis	38
14	Neuronal Sodium-Channel α1-Subunit Mutations in Generalized Epilepsy with Febrile Seizures Plus 2001 ·The American Journal of Human Genetics ·Robyn H. Wallace, Ingrid E. Scheffer, Shaun Barnett, (unknown), Leanne M. Dibbens, R. Desai, Tally Lerman‐Sagie, Dorit Lev, Aziz Mazarib, Nathan Brand, Bruria Ben‐Zeev, Igor Goikhman, Rita Singh, Gabriel Kremmidiotis, Alison Gardner, G.R. Sutherland, Alfred L. George, John C. Mulley, Samuel F. Berkovic	272
15	Molecular and Functional Analyses of the Human and Mouse Genes Encoding AFG3L1, a Mitochondrial Metalloprotease Homologous to the Human Spastic Paraplegia Protein 2001 ·Genomics ·Gabriel Kremmidiotis, Alison Gardner, (unknown), Anna Savoia, Grant R. Sutherland, David F. Callen	38
16	The Batten disease gene product (CLN3p) is a Golgi integral membrane protein 1999 ·Human Molecular Genetics ·Gabriel Kremmidiotis	56
17	Heterogeneity of CD44 expression among human B‐cell subpopulations 1998 ·Tissue Antigens ·Gabriel Kremmidiotis, J. Ridings, Martin J. Hicks, Ian Beckman, (unknown), Robert A. Collins, Heddy Zola	7
18	Genomic Structure and Complete Nucleotide Sequence of the Batten Disease Gene,CLN3 1997 ·Genomics ·Hannah M. Mitchison, Patricia B. Munroe, Angela O'Rawe, Peter E.M. Taschner, (unknown), Gabriel Kremmidiotis, (unknown), A. Christine Munk, (unknown), John W. Anderson, Terry J. Lerner, Robert K. Moyzis, David F. Callen, Martijn H. Breuning, Norman A. Doggett, R. Mark Gardiner, Sara Mole	43
19	Integration of Transcript and Genetic Maps of Chromosome 16 at Near-1-Mb Resolution: Demonstration of a “Hot Spot” for Recombination at 16p12 1995 ·Genomics ·David F. Callen, Sharon Lane, H.M. Kozman, Gabriel Kremmidiotis, S.A. Whitmore, (unknown), Norman A. Doggett, Naoya Kenmochi, David C. Page, Donna Maglott, William C. Nierman, Katsuji Murakawa, Rebecca Berry, James M. Sikela, Rémi Houlgatte, Charles Auffray, G.R. Sutherland	30
20	Changes in CD44 Expression during B Cell Differentiation in the Human Tonsil 1995 ·Cellular Immunology ·Gabriel Kremmidiotis, Heddy Zola	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact